PDF(Pubmed)
Abstract：
UNASSIGNED: The idiopathic inflammatory myopathies (IIM) are a collection of autoimmune diseases that have a substantial impact on the entire body and include conditions such as dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis, and immune-mediated necrotizing myopathy. These disorders are characterized by symptoms such as muscular weakness, pain, and dermal rash. This systematic review is intended to explore the potential link between bladder cancer and DM/PM.
UNASSIGNED: We performed a comprehensive systematic search on PubMed and Scopus until August 2022 to identify relevant research studies. The studies that met our inclusion criteria focused on patients with urinary bladder cancer and dermatomyositis, and/or polymyositis.
UNASSIGNED: The patients\' median age was 65.5 years (47-79), with the majority being male (15, 39.47%). Bladder cancer manifested before PM/DM in 5 (13.15%) patients, while in the majority of cases occurred after the cancer diagnosis. The stage of cancer at the time of the initial PM/DM diagnosis were mostly locally (11/20, 50%).During the first presentation, the patients had a median creatine kinase level of 2227 U/L, ranging between 44 and 10471. In one case, anti-TIF-1γ antibodies were found to be present. Among the cases with reported medical history (20/38), treatment immediately improved DM symptoms in 16 patients(53.8%) and in 3 patients(15%), symptoms of DM resurfaced during the period after the operation. Death was reported in 14 (36.8%) patients.
UNASSIGNED: In conclusion, our study provides knowledge and understanding for identifying specific risk factors in patients with the coexistence of bladder cancer and DM/PM and their management. During the initial and follow-up screening, age, gender, and the clinicopathological subgroup of myositis should be considered to ensure proper management of the condition.
UNASSIGNED: We performed a comprehensive systematic search on PubMed and Scopus until August 2022 to identify relevant research studies. The studies that met our inclusion criteria focused on patients with urinary bladder cancer and dermatomyositis, and/or polymyositis.
UNASSIGNED: The patients\' median age was 65.5 years (47-79), with the majority being male (15, 39.47%). Bladder cancer manifested before PM/DM in 5 (13.15%) patients, while in the majority of cases occurred after the cancer diagnosis. The stage of cancer at the time of the initial PM/DM diagnosis were mostly locally (11/20, 50%).During the first presentation, the patients had a median creatine kinase level of 2227 U/L, ranging between 44 and 10471. In one case, anti-TIF-1γ antibodies were found to be present. Among the cases with reported medical history (20/38), treatment immediately improved DM symptoms in 16 patients(53.8%) and in 3 patients(15%), symptoms of DM resurfaced during the period after the operation. Death was reported in 14 (36.8%) patients.
UNASSIGNED: In conclusion, our study provides knowledge and understanding for identifying specific risk factors in patients with the coexistence of bladder cancer and DM/PM and their management. During the initial and follow-up screening, age, gender, and the clinicopathological subgroup of myositis should be considered to ensure proper management of the condition.
摘要：
■特发性炎性肌病（IIM）是对整个身体有重大影响的自身免疫性疾病的集合，包括皮肌炎（DM）等病症，多发性肌炎(PM),散发性包涵体肌炎，和免疫介导的坏死性肌病。这些疾病的特征是肌肉无力等症状，疼痛,还有皮肤皮疹.本系统综述旨在探讨膀胱癌与DM/PM之间的潜在联系。
■我们对PubMed和Scopus进行了全面的系统搜索，直到2022年8月，以确定相关的研究。符合我们纳入标准的研究集中于膀胱癌和皮肌炎患者，和/或多发性肌炎。
■患者的中位年龄为65.5岁（47-79岁），大多数是男性（15，39.47%）。5例（13.15%）患者在PM/DM前表现为膀胱癌，而大多数病例发生在癌症诊断后。最初PM/DM诊断时的癌症阶段主要是局部的（11/20，50％）。在第一次演讲中，患者的肌酸激酶水平中位数为2227U/L，介于44和10471之间。在一个案例中,发现存在抗TIF-1γ抗体。在有病史报告的病例中（20/38），治疗立即改善了16例患者（53.8%）和3例患者（15%）的DM症状，DM的症状在术后期间出现。14例（36.8%）患者报告死亡。
■总而言之，我们的研究为确定膀胱癌和DM/PM共存患者的特定危险因素及其管理提供了知识和理解.在初始和后续筛查中，年龄,性别,应考虑肌炎的临床病理亚组，以确保对病情的适当管理。
■我们对PubMed和Scopus进行了全面的系统搜索，直到2022年8月，以确定相关的研究。符合我们纳入标准的研究集中于膀胱癌和皮肌炎患者，和/或多发性肌炎。
■患者的中位年龄为65.5岁（47-79岁），大多数是男性（15，39.47%）。5例（13.15%）患者在PM/DM前表现为膀胱癌，而大多数病例发生在癌症诊断后。最初PM/DM诊断时的癌症阶段主要是局部的（11/20，50％）。在第一次演讲中，患者的肌酸激酶水平中位数为2227U/L，介于44和10471之间。在一个案例中,发现存在抗TIF-1γ抗体。在有病史报告的病例中（20/38），治疗立即改善了16例患者（53.8%）和3例患者（15%）的DM症状，DM的症状在术后期间出现。14例（36.8%）患者报告死亡。
■总而言之，我们的研究为确定膀胱癌和DM/PM共存患者的特定危险因素及其管理提供了知识和理解.在初始和后续筛查中，年龄,性别,应考虑肌炎的临床病理亚组，以确保对病情的适当管理。
